- Report
- December 2022
- 83 Pages
North America
From €1360EUR$1,500USD£1,176GBP
Minimal Residual Disease (MRD) Testing is a type of In Vitro Diagnostics (IVD) used to detect the presence of cancer cells in a patient's body. It is used to monitor the effectiveness of cancer treatments and to detect the recurrence of cancer. MRD testing is typically performed on a sample of bone marrow or peripheral blood, and can detect cancer cells at levels as low as one in a million. It is used to detect the presence of cancer cells in patients with leukemia, lymphoma, and multiple myeloma.
MRD testing is a rapidly growing market, driven by the increasing prevalence of cancer and the need for more accurate and sensitive diagnostic tests. The development of new technologies, such as next-generation sequencing and flow cytometry, has enabled more accurate and sensitive MRD testing.
Companies in the MRD testing market include Abbott, Agilent Technologies, Bio-Rad Laboratories, Becton Dickinson, and Roche Diagnostics. Show Less Read more